Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction (AMICI)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Teva Pharmaceuticals USA
Information provided by (Responsible Party):
Mesoblast, Ltd.
ClinicalTrials.gov Identifier:
NCT01781390
First received: January 14, 2013
Last updated: September 13, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)